Crispr Therapeutics is trading 6.05% up at $61.63, with no new company-specific announcement identified for August 21, 2026; the gain appears driven by stock-specific positioning or a delayed reaction.
- August 3 earnings showed a narrower-than-expected second-quarter loss and stronger revenue.
- Upcoming clinical data remain scheduled for August 28.
- The broader biotech sector is declining, unlike today’s gain.